GD2 oligosaccharide: target for cytotoxic T lymphocytes - PubMed (original) (raw)

GD2 oligosaccharide: target for cytotoxic T lymphocytes

X J Zhao et al. J Exp Med. 1995.

Abstract

Carbohydrate antigens rarely provide target epitopes for cytotoxic T lymphocytes (CTL). Disialoganglioside GD2 is a glycolipid expressed at high levels in human tumors and a small group of murine lymphomas (EL4, RBL5, RMA, RMA-S, A13, and BALBRVE). Immunization of C57B1/6 mice with irradiated EL4 cells stimulated a specific CTL response and protected these animals from engraftment of EL4 lymphoma. The CTL activity resided in the CD4-CD8+ population, was dependent on T cell receptor alpha/beta, and was not removed by anti-natural killer cell immunoabsorption, but was restricted to GD2 and H-2b bearing targets. CTL activity could be completely inhibited by GD2-oligosaccharide-specific monoclonal antibodies and their F(ab')2 fragments, but not by immunoglobulin G3 myelomas or antibodies against GD3 or GM2. Soluble GD2 did not inhibit specific tumor lysis. RMA-S lymphoma cells (GD2+H-2b-TAP2 deficient) were resistant to GD2-specific CTL. Sialic acid-containing peptides eluted from EL4 lymphoma cells could (a) stabilize H-2 molecules on RMA-S cells and (b) sensitize them for GD2-specific CTL. Control peptides (derived from vesicular stomatitis virus nucleoprotein peptide and GD2-negative lymphomas) could also stabilize H-2 on RMA-S, but were resistant to GD2-specific CTL. These H-2-binding peptides could be purified by anti-GD2 affinity chromatography. We postulate a new class of naturally occurring epitopes for T cells where branched-chain oligosaccharides are linked to peptides with anchoring motifs for the major histocompatibility complex class I pocket. While analogous to the haptens trinitrophenyl and O-beta-linked acetyl-glucosamine, the potential implications of natural carbohydrates as antigenic epitopes for CTL in biology are considerable.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7629-33 - PubMed
    1. Immunol Lett. 1993 Jan;35(1):63-8 - PubMed
    1. Int J Cancer. 1993 May 28;54(3):499-505 - PubMed
    1. J Immunol. 1993 Jul 15;151(2):678-87 - PubMed
    1. Int J Cancer. 1993 Sep 30;55(3):465-70 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources